NFE2L2 and squamous cell carcinoma: They identified recurrent mutations in MAPK, and mutations in genes such as HLA-B, EP300, FBXW7, NFE2L2,TP53 and ERBB2 in 79 primary squamous cell carcinomas and that of ELF3 and CBFB in 24 adenocarcinomas [6].